Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck

被引：7

作者：

Suzuki, Shinsuke ^{[1
]}

Toyoma, Satoshi ^{[1
]}

Tomizawa, Hiroki ^{[1
]}

Yamada, Toshiki ^{[1
]}

Iikawa, Nobuko ^{[1
]}

Shiina, Kazuhiro ^{[1
]}

Saito, Hidekazu ^{[1
]}

Koizumi, Koh ^{[1
]}

Kawasaki, Yohei ^{[1
]}

Yamada, Takechiyo ^{[1
]}

机构：

[1] Akita Univ, Dept Otorhinolaryngol & Head & Neck Surg, Grad Sch Med, Akita 0108543, Japan

来源：

AURIS NASUS LARYNX | 2020年 / 47卷 / 03期

关键词：

Head and neck squamous cell carcinoma; Immune checkpoint inhibitor; Nivolumab; Chemotherapy; Recurrence; Metastasis; INVESTIGATORS CHOICE; RESPONSE RATES; RECURRENT; INHIBITORS; CETUXIMAB; THERAPY; CANCER; TRIAL;

D O I：

10.1016/j.anl.2019.06.004

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results against squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum-based therapy. However, treatment alternatives for patients with nivolumab-refractory are limited, and a constant opinion is not provided. Recently, accumulating studies have demonstrated that chemotherapy after immune checkpoint inhibitor treatment may induce better objective responses in patients with advanced non-small cell lung cancer. However, there are few reports on the increased effect of chemotherapy after nivolumab treatment in SCCHN. Therefore, cases must be accumulated to identify patients with nivolumab-refractory SCCHN who may benefit from chemotherapy. Here, we present patients with SCCHN who exhibited a significant response to chemotherapy after nivolumab treatment. (C) 2019 Elsevier B.V. All rights reserved.

引用

页码：485 / 488

页数：4

共 50 条

[1] Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck
Reverdy, Thibaut
Varnier, Romain
de Talhouet, Solene
Duplomb, Sophie
Bruyas, Amandine
[J]. ORAL ONCOLOGY, 2023, 145
[2] Nivolumab in squamous cell carcinoma of the head and neck
Specenier, Pol
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (05) : 409 - 420
[3] Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Saleh, K.
Texier, M.
Iacob, M.
Daste, A.
Fayette, J.
Lefebvre, G.
Saada, E. B.
Zanetta, S.
Vinches, M.
Toullec, C.
Salas, S.
Kaminsky-Forrett, M-C.
Johnson, A. C.
Sire, C.
Khalife-saleh, N.
Ferrand, F. R.
Monard, L.
Auperin, A.
Even, C.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S591 - S591
[4] Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer
Sato, Yasuyoshi
Fukuda, Naoki
Fujiwara, Y. U.
Wang, Xiaofei
Urasaki, Tetsuya
Ohmoto, Akihiro
Nakano, Kenji
Ono, Makiko
Tomomatsu, Junichi
Mitani, Hiroki
Takahashi, Shunji
[J]. IN VIVO, 2021, 35 (02): : 1211 - 1215
[5] Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma
Ueta, Reio
Imai, Hiroo
Saijo, Ken
Kawamura, Yoshifumi
Kodera, Shuto
Komine, Keigo
Ouchi, Kota
Kasahara, Yuki
Taniguchi, Sakura
Yoshida, Yuya
Sasaki, Keiju
Shirota, Hidekazu
Takahashi, Masanobu
Ishioka, Chikashi
[J]. ONCOLOGY, 2024, 102 (03) : 252 - 259
[6] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L.
Blumenschein, G., Jr.
Fayette, J.
Guigay, J.
Colevas, A. D.
Licitra, L.
Harrington, K.
Kasper, S.
Vokes, E. E.
Even, C.
Worden, F.
Saba, N. F.
Iglesias Docampo, L. C.
Haddad, R.
Rordorf, T.
Kiyota, N.
Tahara, M.
Monga, M.
Lynch, M.
Geese, W. J.
Kopit, J.
Shaw, J. W.
Gillison, M. L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1856 - 1867
[7] Nivolumab for recurrent squamous-cell carcinoma of the head and neck
[J]. British Dental Journal, 2016, 221 (10) : 632 - 632
[8] Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma
Wakasaki, Takahiro
Yasumatsu, Ryuji
Uchi, Ryutaro
Taura, Masahiko
Matsuo, Mioko
Komune, Noritaka
Nakagawa, Takashi
[J]. AURIS NASUS LARYNX, 2020, 47 (01) : 116 - 122
[9] Efficacy and safety of nivolumab for previously treated non-squamous cell carcinoma of the head and neck
Suzuki, Chiaki
Kiyota, Naomi
Imamura, Yoshinori
Rikitake, Junpei
Sai, Satoshi
Kimbara, Shiro
Hyogo, Yasuko
Nagatani, Yoshiaki
Funakoshi, Yohei
Toyoda, Masanori
Minami, Hironobu
[J]. ANNALS OF ONCOLOGY, 2018, 29
[10] Molecular progression of head and neck squamous cell carcinoma
Saha S.K.
Maiti G.P.
Roychoudhury S.
Panda C.K.
[J]. The Nucleus, 2017, 60 (2) : 111 - 119

← 1 2 3 4 5 →